Live Breaking News & Updates on Enalare Therapeutics Announces Partnership

Enalare Therapeutics Announces Partnership with BARDA to Advance Development of its Lead Product ENA-001
Posted Apr 29, 2021
The Funding Will Accelerate Development of an Intramuscular Formulation of a Novel Agnostic  Respiratory Stimulant to Treat Life-threatening Respiratory Depression 
PRINCETON, N.J. - Enalare Therapeutics Inc. announced today that it has received an initial contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to support development of the company’s lead product ENA-001. The funding will be used to advance development of an intramuscular (IM) formulation for ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action and potential broad applications as an agnostic respiratory stimulant. The funding is provided via the BARDA Division of Research, Innovation, a ....

Joe Pergolizzi , Chemical Medical Countermeasures Mcms Program , Biomedical Advanced Research , Us Department Of Health , Human Services , Enalare Therapeutics Announces Partnership , Drug Administration , Development Authority , Enalare Therapeutics Inc , Office Of The , Division Of Research , Therapeutics Announces Partnership , Lead Product , Funding Will Accelerate Development , Intramuscular Formulation , Novel Agnostic , Respiratory Stimulant , Treat Life Threatening Respiratory Depression , Assistant Secretary , New Chemical Entity , Repurposing Drugs , Chemical Threats , Medical Countermeasures , Chief Rd Officer , எங்களுக்கு துறை ஆஃப் ஆரோக்கியம் , மனிதன் சேவைகள் ,